Psyence Biomedical Ltd. - Common Shares (PBM)

Last Price8.9700

Change+0.00 (0.00%)

NASDAQ · Last Trade: Apr 23rd, 6:56 AM EDT

Detailed Quote

Previous Close	8.970
Open	-
Bid	8.100
Ask	8.290
Day's Range	N/A - N/A
52 Week Range	0.3743 - 16.96
Volume	52,013
Market Cap	-
PE Ratio (TTM)	-
EPS (TTM)	-
Dividend & Yield	N/A (N/A)
1 Month Average Volume	6,929,953

About Psyence Biomedical Ltd. - Common Shares (PBM)

Psyence Biomedical Ltd. is a leading biotechnology company focused on harnessing the therapeutic potential of psychedelics to develop innovative treatments for mental health conditions and other ailments. The company is dedicated to conducting research and clinical trials to better understand the efficacy and safety of its psychedelic compounds, aiming to advance the field of mental health care. Through the development of proprietary formulations and treatment protocols, Psyence strives to create evidence-based solutions that can improve the quality of life for patients suffering from conditions such as depression, anxiety, and post-traumatic stress disorder. Read More

News & Press Releases

Which stocks are gapping on Wednesday?chartmill.com

Via Chartmill · April 22, 2026

Which stocks are moving before the opening bell on Wednesday?chartmill.com

Via Chartmill · April 22, 2026

Traders are paying attention to the gapping stocks in Tuesday's session.chartmill.com

Via Chartmill · April 21, 2026

Small-Cap Medical Stocks: ATAI, CMPS, NDRA, PBM in Focus as U.S. Policy Accelerates Psychedelic Research

A renewed spotlight is forming around a group of small-cap healthcare companies as U.S. policy shifts toward accelerating research into psychedelic-based therapies for mental health disorders. Following a recent executive order aimed at expanding research pathways, companies below are drawing increased investor and industry attention as innovation and regulatory momentum converge.

Via AB Newswire · April 20, 2026

Why Is PBM Stock Drawing So Much Investor Interest Today?stocktwits.com

Via Stocktwits · February 2, 2026

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Sciencestocktwits.com

Via Stocktwits · December 9, 2025

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Programstocktwits.com

Via Stocktwits · November 25, 2025

Top movers analysis one hour before the close of the markets on 2026-04-20: top gainers and losers in today's session.chartmill.com